Navigation Links
Five-Year Data Confirm That Early Treatment with Betaseron(R) at First Sign of Disease Can Delay Progression to MS
Date:9/20/2008

ple sclerosis.

The most commonly reported adverse reactions are lymphopenia, injection-site reaction, asthenia, flu-like symptom complex, headache and pain. Gradual dose titration and use of analgesics during treatment initiation may help reduce flu-like symptoms. Betaseron should be used with caution in patients with depression. Injection-site necrosis has been reported in four percent of patients in controlled trials. Patients should be advised of the importance of rotating injection sites. Female patients should be warned about the potential risk to pregnancy. Cases of anaphylaxis have been reported rarely. See "Warnings," "Precautions," and "Adverse Reactions" sections of full Prescribing Information. More information, including the full Prescribing Information, is available at http://www.betaseron.com.

About Multiple Sclerosis

MS is a chronic, progressive disease of the central nervous system and the likelihood of disability increases the longer someone has MS. Symptoms of MS vary from person to person and can be unpredictable. They may include: fatigue or tiredness, dimness of vision in one or both eyes, weakness in one or more extremities, numbness and tingling in the face, arms, legs and trunk of the body, spasticity (muscle stiffness), dizziness, double vision, slurred speech and loss of bladder control.

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals business of Bayer HealthCare LLC, a subsidiary of Bayer AG. Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical products industry, and combines the activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. Bayer HealthCare Pharmaceuticals comprises the following business units: Women's Healthcare, Diagnostic Imaging, General Medicine, which includes Cardiology and Primary Car
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
2. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
3. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
4. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
5. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
6. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
7. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
8. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
9. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
10. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
11. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009).../PRNewswire/--SpartaSystems,Inc.,themakerofTrackWi...compliancesolutions,todayannouncedthatSSLInternati...theparentcompanyforgloballyrecognizedbrandssuchasD...alityManagementSystem(EQMS).Thecompanyisnowleverag...tyoperationsthatincludeCorrectiveandPreventiveActi...
(Date:11/24/2009)...ewswire/--AmbitBiosciencesCorporationannouncedtoda...20,anovelsecondgenerationFLT3inhibitor,inAMLatthe5...beheldinNewOrleans,LA,December5-8,2009.Anoralprese...aseImonotherapysafetystudyinadultswithacutemyeloid...resentedevaluatingtheeffectofAC220monotherapyandin...
(Date:11/24/2009)...,Nov.24/PRNewswire-FirstCall/--CardioGenicsHolding...yandproductstargetingtheimmunoassaysegmentoftheIVD...himie")isprogressingtothenextphaseofthecommerciali...gneticBeads("Beads"). ,, PertheagreementwithMer...ssuppliedMerckChimiewithitsproprietarysilvercoated...
Breaking Medicine Technology:SSL International plc Embraces TrackWise(R) Software for Global Quality and Compliance Efforts 2SSL International plc Embraces TrackWise(R) Software for Global Quality and Compliance Efforts 3Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting 2Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting 3CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 2CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads 32009 Houston Juneteenth Multicultural Health Festival Becomes Largest Health Event in Texas 3A Festival Moves Indoors to the Cool George R Brown 48107 12009 Houston Juneteenth Multicultural Health Festival Becomes Largest Health Event in Texas 3A Festival Moves Indoors to the Cool George R Brown 48107 22009 Catholic Health Assembly to Focus on Hope in a Time of Hardship and Adapting for the Future in a Time of Health Reform 48105 12009 Catholic Health Assembly to Focus on Hope in a Time of Hardship and Adapting for the Future in a Time of Health Reform 48105 22009 Catholic Health Assembly to Focus on Hope in a Time of Hardship and Adapting for the Future in a Time of Health Reform 48105 3Studies Show AFRESA 28R 29 Controls Post Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients 4548 1Studies Show AFRESA 28R 29 Controls Post Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients 4548 2Studies Show AFRESA 28R 29 Controls Post Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients 4548 3Studies Show AFRESA 28R 29 Controls Post Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients 4548 4
...y study shows clinical improvement in patients wit... Current treatment options have limited benefit f... incurable blood vessel disease, -- Imatinib me...ertain cancers, known to inhibit protein asso... potential of imatinib mesylate in PAH in 200...
...s the efficacy of new device for detecting polyps ...lonoscopy, ORLANDO, Fla., Oct. 7 At the American...ting in Orlando (ACG 2008), renowned,gastroenterol...multi-institutional clinical study that evaluated ...new device that is designed to improve the ability...
Other Medicine Technology:Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 2Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 3Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 4Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 5Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 6Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 7Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 8Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 9Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 10Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 11Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 12National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 2National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 3National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 4National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 5
(Date:11/25/2009)...ivors often plagued by neurological symptoms, stud...ay News) -- Neurological side effects are among th...of testicular cancer who were treated with cisplat... The study included 1,409 Norwegian men treated fo...94 who took part in a follow-up survey conducted f...
(Date:11/25/2009)..., ARLINGTON,Va.,Nov.25/PRNewswire-USNewswire/--T...ventHealthCareFraudActof2009,"S.2128,whichisdesign...topreventfraudinMedicare.ThebillwasintroducedbySen...nsseveralprovisionstheAmericanAssociationforHomeca...heAssociationproposedtoCongressinFebruary.Thosepro...
(Date:11/25/2009)...drug used to treat colorectal cancer also can reve...ed first-line therapy for the disease, researchers...is week. , Mntrier,s disease causes thickening of... and vomiting, as well as anemia and swelling in t...re at increased risk for gastric cancer. Previousl...
(Date:11/25/2009)...y found puffs of air on flesh that mimicked parts ..., WEDNESDAY, Nov. 25 (HealthDay News) -- People c...their skin, new research shows. , In fact, sens... of speech actually helped people decipher sounds ...ve never been able to show whether we could use ta...
(Date:11/25/2009)... BioSpace.com, the premier re...nveiled the third edition of the BioForest™ ... Englewood, CO (Vocus) November 25, 2009 -- ...e careers and information, unveiled the third edit...orning., , , , ,This regional campaign is a promo...
Breaking Medicine News(10 mins):Health News:American Association for Homecare Endorses New U.S. Senate Bill, the 'Prevent Health Care Fraud Act of 2009' 2Health News:Vanderbilt scientists report first effective medical therapy for rare stomach disorder 2Health News:Your Skin Can Help Your Ears Listen 2Health News:Your Skin Can Help Your Ears Listen 3Health News:BioSpace Showcases Leading Life-Science Companies in the Northwest 2
...al traits, susceptibility to certain diseases , .... researchers have identified 1,362 copy number va...1,972 in whites. , CNVs -- differences in gene co...ociated with behavioral traits or increased suscep...
...f getting blood sugar disease, survey finds , ...han half of Americans fear developing diabetes, bu... their odds of getting the blood sugar disease, a ... president-elect for medicine and science for the ...
... (NIH) will commit roughly $60 million from Ameri...t autism research and meet objectives set forth ea...he Request for Applications is the largest funding...o finding the causes and treatments for autism. , ...
...irginia Commonwealth University School of Medicine...th hearing loss actually re-route the sense of tou...study, published online in the Early Edition of th...ry system of adult animals. Cross-modal plasticity...
...er of autism services shares events that raise awa... MINNEAPOLIS, March 24 Autism is the fastest-grow...g 1 in 150 children. Every 20 minutes, a child is ...ty,s most urgent needs. With these powerful statis...
... a national investment consulting firm, has expand...tley, CFA, CAIA. , , LCG,s ownership provides sig...talent in the consulting industry. LCG rewards ow...ulting services for corporations, utilities, endow...
Other Medicine News:Health News:Study IDs Variations in Black, White Genomes 2Health News:Many Americans Fear Being Diagnosed With Diabetes 2Health News:Many Americans Fear Being Diagnosed With Diabetes 3Health News:NIH will use $60 million in Recovery Act funds to support strategic autism research 2Health News:NIH will use $60 million in Recovery Act funds to support strategic autism research 3Health News:April is Autism Awareness Month 2Health News:April is Autism Awareness Month 3
Cortac Cortical Electrodes
...s designed for laboratories looking for time and c...system operation in terms of easy reagent cassette... on-board stability., ,URISYS 2400 is a fully...lk-away capability for medium to high volume labor...
Electrode
The Spider Limited Wrist Fusion System
Medicine Products: